X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs MERCK LTD - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER MERCK LTD PFIZER/
MERCK LTD
 
P/E (TTM) x 34.1 47.0 72.6% View Chart
P/BV x 4.8 6.9 70.4% View Chart
Dividend Yield % 0.7 0.5 142.7%  

Financials

 PFIZER   MERCK LTD
EQUITY SHARE DATA
    PFIZER
Mar-18
MERCK LTD
Dec-17
PFIZER/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs2,3651,358 174.2%   
Low Rs1,625933 174.2%   
Sales per share (Unadj.) Rs430.3665.0 64.7%  
Earnings per share (Unadj.) Rs78.756.6 139.1%  
Cash flow per share (Unadj.) Rs93.272.5 128.6%  
Dividends per share (Unadj.) Rs20.0015.00 133.3%  
Dividend yield (eoy) %1.01.3 76.5%  
Book value per share (Unadj.) Rs586.5441.7 132.8%  
Shares outstanding (eoy) m45.7516.60 275.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.61.7 269.2%   
Avg P/E ratio x25.320.2 125.2%  
P/CF ratio (eoy) x21.415.8 135.5%  
Price / Book Value ratio x3.42.6 131.2%  
Dividend payout %25.426.5 95.8%   
Avg Mkt Cap Rs m91,27119,011 480.1%   
No. of employees `0002.61.5 170.3%   
Total wages/salary Rs m3,1431,696 185.3%   
Avg. sales/employee Rs Th7,484.87,150.0 104.7%   
Avg. wages/employee Rs Th1,195.01,098.7 108.8%   
Avg. net profit/employee Rs Th1,369.1608.2 225.1%   
INCOME DATA
Net Sales Rs m19,68511,040 178.3%  
Other income Rs m1,143240 476.8%   
Total revenues Rs m20,82811,279 184.7%   
Gross profit Rs m5,0031,376 363.5%  
Depreciation Rs m663264 250.9%   
Interest Rs m40-   
Profit before tax Rs m5,4791,352 405.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m1,878583 322.3%   
Profit after tax Rs m3,601939 383.4%  
Gross profit margin %25.412.5 203.9%  
Effective tax rate %34.343.1 79.5%   
Net profit margin %18.38.5 215.0%  
BALANCE SHEET DATA
Current assets Rs m24,1677,523 321.2%   
Current liabilities Rs m9,5442,253 423.7%   
Net working cap to sales %74.347.7 155.6%  
Current ratio x2.53.3 75.8%  
Inventory Days Days5552 105.6%  
Debtors Days Days2941 70.8%  
Net fixed assets Rs m9,5141,240 767.4%   
Share capital Rs m458166 275.6%   
"Free" reserves Rs m26,3757,167 368.0%   
Net worth Rs m26,8327,333 365.9%   
Long term debt Rs m250-   
Total assets Rs m36,9009,912 372.3%  
Interest coverage x1,305.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.1 47.9%   
Return on assets %9.89.5 103.1%  
Return on equity %13.412.8 104.8%  
Return on capital %20.420.8 98.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m221,015 2.2%   
Fx outflow Rs m1,4893,043 48.9%   
Net fx Rs m-1,466-2,028 72.3%   
CASH FLOW
From Operations Rs m3,318537 618.3%  
From Investments Rs m-2,383-476 500.3%  
From Financial Activity Rs m-1,104-220 502.0%  
Net Cashflow Rs m-169-160 105.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 51.8 123.4%  
Indian inst/Mut Fund % 7.5 18.2 41.2%  
FIIs % 4.9 1.0 490.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 29.1 81.4%  
Shareholders   85,207 28,591 298.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   TORRENT PHARMA  ALKEM LABORATORIES  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 16, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS